Use of aerosolized antibiotics in patients with cystic fibrosis

Chest

Volumn 116, Issue 3, 1999, Pages 775-788

  Campbell III, Preston W ^b   Saiman, Lisa ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA LACTAM ANTIBIOTIC; CARBENICILLIN; CEFALORIDINE; CIPROFLOXACIN; COLISTIN; GENTAMICIN; PENICILLIN DERIVATIVE; POLYMYXIN; POLYMYXIN DERIVATIVE; TOBRAMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; BRONCHOSPASM; CLINICAL PROTOCOL; CONFERENCE PAPER; CYSTIC FIBROSIS; DOSE CALCULATION; DRUG EFFICACY; DRUG INDICATION; DRUG PENETRATION; EVIDENCE BASED MEDICINE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG INFECTION; MEDICAL NEBULIZER; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; OTOTOXICITY; PATIENT MONITORING; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 0032840712     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.116.3.775     Document Type: Conference Paper

References (47)

1. 1 Littlewood JM, Smye SW, Cunliffe H. Aerosol antibiotic treatment in cystic fibrosis. Arch Dis Child 1993; 68:788-792
2. 2 Touw DJ, Brimicombe RW, Hodson ME, et al. Inhalation of antibiotics in cystic fibrosis. Eur Respir J 1995; 8:1594-1604
3. 3 Smith AL, Ramsey BW. Aerosol administration of antibiotics. Respiration 1995; 62(suppl 1):19-24
4. 4 United States Preventive Services Task Force. Guide to clinical preventive services. Baltimore, MD: Williams & Wilkins, 1989; 263
5. 5 Hodson ME, Penketh ARL, Batten JC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 1981; 2:1137-1139
6. 6 Wall MA, Terry AB, Eisenberg J, et al. Inhaled antibiotics in cystic fibrosis [letter]. Lancet 1983; 1:1325
7. 7 Carswell F, Ward C, Cook DA, et al. A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with cystic fibrosis. Br J Dis Chest 1987; 81:356-360
8. 8 Stead RJ, Hodson ME, Batten JC. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest 1987; 81:272-279
9. 9 Steinkamp G, Tummler B, Gappa M, et al. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol 1989; 6:91-98
10. 10 Kun P, Landau LI, Phelan PD. Nebulized gentamicin in children and adolescents with cystic fibrosis. Anst J Paediatr 1984; 20:43-45
11. 11 MacLusky IB, Gold R, Corey M, et al. Long-term effects of inhaled tobramycin in patients with Pseudomonas aeruginosa. Pediatr Pulmonol 1989; 7:42-48
12. 12 Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993; 328:1740-1746
13. 13 Smith AL, Ramsey BW, Hedges DL, et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol 1989; 7:265-271
14. 14 Levy J, Smith AL, Kenny MA, et al. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. J Infect Dis 1983; 148:1069-1076
15. 15 Mendelman PM, Smith AL, Levy J, et al. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985; 132:761-765
16. 16 Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340:23-30
17. 17 Stephens D, Garey N, Isles A, et al. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatr Infect Dis J 1983; 2:209-211
18. 18 Schaad RB, Wedgwood-Krucko J, Suter S, et al. Efficacy of inhaled as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr 1987; 111:599-605
19. 19 Littlewood JM, Miller MG, Ghoneim AT, et al. Nebulised colomycin for use in early pseudomonas colonisation in cystic fibrosis. Lancet 1985; 1:865
20. 20 Jensen T, Pedersen SS, Garne S, et al. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 1987; 19:831-838
21. 21 Bauldoff GS, Nunley DR, Manzetti JD, et al. Use of aerosolized colistin sodium in cystic fibrosis patients awaiting lung transplantation. Transplantation 1997; 64:748-752
22. 22 Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991; 338:725-726
23. 23 Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23:330-335
24. 24 Vazquez C, Municio M, Corera M, et al. Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Acta Paediatr 1993; 82:308-309
25. 25 Feeley TW, du Moulin GC, Hedley-Whyte J, et al. Aerosol polymyxin and pneumonia in seriously ill patients. N Engl J Med 1975; 293:471-475
26. 26 Simmonds EJ, Conway SP, Ghonheim ATM, et al. Pseudomonas cepacia: a new pathogen in patients with cystic fibrosis referred to a large centre in the United Kingdom. Arch Dis Child 1990; 65:874-877
27. 27 Trissel LA. Handbook on injectable drugs. 4th ed. 1996
28. 28 Nolan G, McIvor P, Leson H, et al. Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin. J Pediatr 1982; 101:626-630
29. 29 Potter JL, Matthews LW, Spector S, et al. Complex formation between basic antibiotics and deoxyribonucleic acid in human pulmonary secretions. Pediatrics 1965; 36:714-720
30. 30 Matthews L, Doershuk CF, Wise M, et al. A therapeutic regimen for patients with cystic fibrosis. J Pediatr 1964; 65:558-564
31. 31 Valcke Y, Pauwels R, Van Der Straeten M. Pharmacokinetics of antibiotics in the lung. Eur Respir J 1990; 3:715-722
32. 32 Hunt BE, Weber A, Berger A, et al. Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob Agents Chemother 1995; 39:34-39
33. 33 Smith AL, Redding G, Doershuk C, et al. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr 1988; 112:547-554
34. 34 Shaw PK, Braun TL, Liebergen A, et al. Aerosolized tobramycin pharmacokinetics in cystic fibrosis patients. J Pediatr Pharm Prac 1997; 2:23-26
35. 35 Eisenberg J, Pepe M, Williams-Warren J, et al. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Chest 1997; 111:955-962
36. 36 Brain JD, Valberg PA. Deposition of aerosol in the respiratory tract. Am Rev Respir Dis 1979; 120:1325-1373
37. 37 Wolff RK, Niver RW. Generation of aerosolized drugs. J Aerosol Med 1994; 7:89-106
38. 38 Nerbrink O, Dahlback M, Hansson HC. Why do medical nebulizers differ in their output and particle size characteristics? J Aerosol Med 1997; 7:259-276
39. 39 Coates AI, MacNeish CF, Lands LC, et al. A comparison of vented versus unvented nebulizers for the delivery of tobramycin. Pediatr Pulmonol 1997; 514:288
40. 40 Smaldone GC. Deposition of nebulized drugs: is the pattern important? J Aerosol Med 1994; 7:525-533
41. 41 Laube BL. In vivo measurements of aerosol dose and distribution clinical relevance. J Aerosol Med 1996; 6:9577-9590
42. 42 Burger GT, Renne RA, Sagartz JW, et al. Histologic changes in the respiratory tract induced by inhalation of xenobiotics. Toxicol Appl Pharmacol 1989; 101:521-542
43. 43 Koch-Weser J, Sidel VW, Federman EB, et al. Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72:857-868
44. 44 Maddison J, Dodd M, Webb AK. Nebulized colistin causes chest tightness in adults with cystic fibrosis. Respir Med 1994; 88:145-147
45. 45 Cystic Fibrosis Foundation. Clinical practice guidelines 1997; 2:30
46. 46 Cystic Fibrosis Foundation. Clinical practice guidelines 1997; 2:12
47. 47 Microbiology and Infections Disease in Cystic Fibrosis, Consensus Conference. Concepts in care. CF Foundation (vol V, section 1); 1994